Preproenkephalin (Penk) is expressed in differentiated osteoblasts, and its Deletion in Hyp Mice partially rescues their bone mineralization defect

Calcified Tissue International

Volumn 86, Issue 4, 2010, Pages 282-293

  Seitz, S ^a   Barvencik, F ^a   Gebauer, M ^a   Albers, J ^a   Schulze, J ^a   Streichert, T ^a   Amling, M ^a   Schinke, T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Mineralization; Osteoblast; Phex; Preproenkephalin; X linked hypophosphatemic rickets

Indexed keywords

PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PREPROENKEPHALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE; X LINKED HYPOPHOSPHATEMIC RICKETS;

ANIMALS; BONE DEMINERALIZATION, PATHOLOGIC; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENKEPHALINS; EPISTASIS, GENETIC; FEMALE; GENE DELETION; GENE EXPRESSION; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MALE; MICE; MICE, TRANSGENIC; OSTEOBLASTS; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PROTEIN PRECURSORS;

EID: 77953231533     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9344-5     Document Type: Article

References (52)

1. Teitelbaum SL, Ross F (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649
2. Harada S, Rodan GA (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349-355
3. Karsenty G (2003) The complexities of skeletal biology. Nature 423:316-318
4. Meier C, Liu PY, Handelsman DJ, Seibel MJ (2005) Endocrine regulation of bone turnover in men. Clin Endocrinol (Oxf) 63:603-616
5. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12
6. Takeda S, Karsenty G (2008) Molecular bases of the sympathetic regulation of bone mass. Bone 42:837-840
7. McKee MD, Addison WN, Kaartinen MT (2005) Hierarchies of extra cellular matrix and mineral organization in bone of the craniofacial complex and skeleton. Cells Tissues Organs 181:176-188
8. Mornet E (2000) Hypophosphatasia: the mutations in the tissuenonspecific alkaline phosphatase gene. Hum Mutat 15:309-315
9. Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS (1999) Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 14:2015-2026
10. Murshed M, Harmey D, Millán JL, McKee MD, Karsenty G (2005) Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 19:1093-1104
11. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL (2004) Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164:1199-1209
12. Fleisch H, Bisaz S (1962) Mechanism of calcification: inhibitory role of pyrophosphate. Nature 195:911
13. The HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130-136
14. Eicher EM, Southard JL, Scriver CR, Glorieux FH (1976) Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci USA 73:4667-4671
15. Strom TM, Francis F, Lorenz B, Böddrich A, EconsMJ, Lehrach H (1997) Pex gene deletions in Gy and Hyp mice provide mouse models forX-linked hypophosphatemia.HumMol Genet 6:165-171
16. Thompson DL, Sabbagh Y, Tenenhouse HS, Roche PC, Drezner MK, Salisbury JL (2002) Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res 17:311-320
17. Nesbitt T, Coffman TM, Griffiths R, Drezner MK (1992) Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 89:1453-1459
18. Turner AJ, Tanzawa K (1997) Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 11:355-364
19. ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
20. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:37419-37426
21. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38-E49
22. Ecarot B, Glorieux FH, Desbarats M, Travers R, Labelle L (1992) Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J Bone Miner Res 7:215-220
23. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD (1998) Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol Endocrinol Metab 275:E700-E708
24. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM et al (2008) Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757-1772
25. Schinke T, Gebauer M, Schilling AF, Lamprianou S, Priemel M, Mueldner C, Neunaber C, Streichert T, Ignatius A, Harroch S, Amling M (2008) The protein tyrosine phosphatase Rptpzeta is expressed in differentiated osteoblasts and affects bone formation in mice. Bone 42:524-534
26. Schilling AF, Schinke T, Münch C, Gebauer M, Niemeier A, Priemel M, Streichert T, Rueger JM, Amlig M (2005) Increased bone formation in mice lacking apolipoprotein E. J Bone Miner Res 20:274-282
27. Rosen H, Krichevsky A, Bar-Shavit Z (1998) The enkephalinergic osteoblast. J Bone Miner Res 13:1515-1520
28. Guo R, Liu S, Spurney RF, Quarles LD (2001) Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 281:E837-E847
29. König M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, Zimmer A (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535-538
30. Schmidt K, Schinke T, Haberland M, Priemel M, Schilling AF, Mueldner C, Rueger JM, Sock E, Wegner M, Amling M (2005) The high mobility group transcription factor Sox8 is a negative regulator of osteoblast differentiation. J Cell Biol 168:899-910
31. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB (1999) Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140:4982-4987
32. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
33. Zagon IS, Verderame MF, McLaughlin PJ (2002) The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 38:351-376
34. Comb M, Rosen H, Seeburg P, Adelman J, Herbert E (1983) Primary structure of the human proenkephalin gene. DNA 2:213-229
35. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM (1984) Endogenous opioids: biology and function. Annu Rev Neurosci 7:223-255
36. Imura H, Kato Y, Nakai Y, Nakao K, Tanaka I, Jingami H, Koh T, Yoshimasa T, Tsukada T, Suda M et al (1985) Endogenous opioids and related peptides: from molecular biology to clinical medicine. The Sir Henry Dale Lecture. J Endocrinol 107:147-157
37. Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J, Bodnar RJ, Pfaff DW (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci USA 98:1958-1963
38. Keshet E, Polakiewicz RD, Itin A, Ornoy A, Rosen H (1989) Proenkephalin A is expressed in mesodermal lineages during organogenesis. EMBO J 8:2917-2923
39. Rosen H, Polakiewicz RD, Benzakine S, Bar-Shavit Z (1991) Proenkephalin A in bone-derived cells. Proc Natl Acad Sci USA 88:3705-3709
40. Schinke T, Liese S, Priemel M, Haberland M, Schilling AF, Catala-Lehnen P, Blicharski D, Rueger JM, Gagel RF, Emeson RB, Amling M (2004) Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res 19:2049-2056
41. Takeda S (2008) Central control of bone remodeling. J Neuroendocrinol 20:802-807
42. Bab I, Zimmer A (2008) Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 153:182-188
43. Sousa DM, Herzog H, Lamghari M (2009) NPY signaling pathway in bone homeostasis: Y1 receptor as a potential drug target. Curr Drug Targets 10:9-19
44. Rowe PS, Matsumoto N, Jo OD, Shih RN, O'Connor J, Roudier MP, Bain S, Liu S, Harrison J, Yanagawa N (2006) Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone 39:773-786
45. Vaisbich MH, Koch VH (2006) Hypophosphatemic rickets: results of a long-term follow-up. Pediatr Nephrol 21:230-234
46. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315
47. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Jüppner H, Strom TM (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250
48. Addison WN, Nakano Y, Loisel T, Crine P, McKee MD (2008) MEPE-ASARMpeptides control extracellularmatrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638-1649
49. Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE (2005) Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36:33-46
50. Addison W, Masica D, Gray J, McKee MD (2010) Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res [Epub ahead of print]. http://www3.interscience. wiley.com/journal/123209974/abstract. doi:10.1359/jbmr.090832
51. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, Quarles LD (2005) Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16:1645-1653
52. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD (2002) Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 71:145-154